



F FOREST LABORATORIES, INC.

2000 ANNUAL REPORT
YEAR ENDED MARCH 31, 2000

Forest Laboratories develops, manufactures and sells both branded and generic forms of ethical products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.

Forest products are marketed principally in the United States and western and eastern Europe. Marketing is conducted by Forest and through independent distributors.

FOREST LABORATORIES, INC.

In the United States, Forest's ethical specialty products are marketed directly by the Company's Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales salesforces. The Company's generic products are marketed directly by its Inwood Laboratories, Inc. subsidiary.

In the United Kingdom, Ireland and certain export markets, Forest products are marketed directly by the Company's subsidiaries, Pharmax Limited and the Tosara Group. Pharmax is a U.K. manufacturer and marketer of a range of specialty pharmaceuticals, including products manufactured by Forest and Tosara.





Forest Laboratories common stock is traded on the New York Stock Exchange, trading symbol: FRX.

FISCAL YEARS ENDED MARCH 31,

(IN THOUSANDS, EXCEPT PER SHARE DATA)

	2000	1999
Net revenues	\$899,301	\$623,988
Income before income taxes	157,447	110,803
Income taxes	44,759	33,630
Net income	112,688	77,173
Earnings per common and common equivalent share - diluted	\$1.28	\$0.90
Weighted average number of common and common equivalent shares outstanding - diluted	87,945	85,956

FINANCIAL HIGHLIGHTS



*Includes \$32,250 paid in connection with a licensing agreement for certain products in early stages of development.